Hematology: Page 5

Australians develop portable fibrinogen blood test

Fibrinogen is a protein necessary for blood clotting, and typically in emergency situations patients must be transported to a hospital or emergency center for diagnostic testing before treatment. Using a glass slide, Teflon film, and a piece of paper, the test can be performed using a fresh whole blood sample, and it removes the need for centralized hospital equipment to detect, monitor, and treat fibrinogen levels.

November 1, 2020

Beckman Coulter debuts new tabletop hematology analyzer

Targeted at mid-volume laboratories, DxH 690T provides similar functionality as Beckman Coulter's flagship DxH 900 large-volume hematology analyzer, but in a tabletop configuration, according to the vendor. The DxH 690T supports Beckman Coulter's Early Sepsis Indicator test for identifying adult patients who either have sepsis or have an increased risk of developing the life-threatening condition, as part of a standard complete blood count (SBC) with differential.

May 19, 2020

Study urges broader genetic testing of breast cancer patients

The National Comprehensive Cancer Network's (NCCN) current guidelines for genetic testing recommend it for women younger than 46 who are diagnosed with breast cancer, regardless of family history or cancer subtype. But expanding the age range for genetic testing would help identify more women with mutations that make them vulnerable, concluded first author Dr. Siddhartha Yadav, a hematology-oncology fellow at the Mayo Clinic in Rochester, MN, and colleagues.

March 3, 2020

XaTek wins FDA designation for blood-clotting sensor

Enabled for Wi-Fi and Bluetooth, ClotChip measures a patient's profile for bleeding risk at the bedside from a single drop of blood obtained from a finger stick, according to the company. The breakthrough device designation will enable the work-in-progress sensor to receive expedited review by the FDA as a technology that could enable more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions, compared with existing approved products.

March 2, 2020

Roche launches Zika blood screening test in Europe

The test screens for the Zika virus in human plasma and is designed for use with the company's cobas 6800/8800 systems. Roche noted that it has been marketing the Zika test for screening blood donations in the U.S. and U.S. territories since 2017, in consultation with the Food and Drug Administration.

December 16, 2019

Pathologists get to the bottom of AML subtypes

AML is a notoriously heterogenous disease, which has made drug development and patient management challenging, though there has been a flurry of approvals of drugs targeting particular mutation subgroups in recent years.

December 11, 2019

AbbVie to deploy Adaptive's clonoSeq test in myeloma trials

Venclexta is currently approved by the U.S. Food and Drug Administration (FDA) for use in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, and in older patients with newly diagnosed acute myeloid leukemia who can't tolerate intensive chemotherapy. It is being tested for a number of additional indications, including multiple myeloma.

December 8, 2019

Low white blood cell count warns of bad outcomes

The retrospective study analyzed data collected by the U.S. Centers for Disease Control and Prevention (CDC) for a sample of 31,178 generally low-risk outpatients enrolled in the National Health and Nutrition Examination Survey (NHANES). The researchers evaluated the associations between lymphopenia; other immunohematologic (IH) abnormalities, i.e., elevation of the inflammation biomarker C-reactive protein (CRP) and abnormal red blood cell distribution width (RDW); and survival, adjusting for clinical variables.

December 2, 2019

Pathologist pens medical mystery | Adapting breast cancer risk scores for men | Hematology market overview

Dear LabPulse Member,

November 25, 2019

Hematology thrives with decentralized approaches

The basis of hematology testing is the complete blood count (CBC), which provides information on blood components: hemoglobin, hematocrit, red blood cells, white blood cells, reticulocytes, and platelets. The CBC is run as part of the normal workup in an annual health exam and for every inpatient. A drop of blood is placed on a microscope slide and stained. The slide is then examined under a microscope and the cells are analyzed.

November 20, 2019

List of Tags

November 6, 2019

Ortho Sera extended blood typing clears FDA

Phenotyping is done prior to blood transfusions to determine if patients have antibodies to various blood group antigens; extended phenotyping is performed when patients may have developed atypical antibodies. According to the company, Ortho Sera covers more than 99% of the most commonly tested antigens. Extended phenotyping is completed in an automated fashion on one platform, with results available in 20 minutes, the company noted in a statement.

October 17, 2019

Previous Page

Page 5 of 7

Next Page